Urothelial Bladder Cancer | Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Urothelial Bladder Cancer

Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O’Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54) Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O’Donnell (25:53) Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43) Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51) CME information and select publications